Assessing the role of PARP inhibitors and immunotherapy in ovarian cancer

1 Views

07/08/23

Anniina Färkkilä, MD, PhD, Helsinki University, Helsinki, Finland, discusses the efficacy of immunotherapy and PARP inhibitors in ovarian cancer. Different tumor microenvironments and genetic drivers can influence the efficacy of PARP inhibitors and novel biomarkers are needed to identify patients who will benefit from PARP inhibitors and immunotherapy. Homologous recombination deﬁciency (HRD) and CD8 T cells have been identified as promising biomarkers in patients. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.